The cost-utility of school-based first permanent molar sealants programs: a Markov model

被引:14
|
作者
Espinoza-Espinoza, Gerardo [1 ,2 ]
Corsini, Gilda [3 ]
Rojas, Ruben [4 ]
Marino, Rodrigo [5 ]
Zaror, Carlos [2 ,6 ]
机构
[1] Univ La Frontera, Dept Publ Hlth, Fac Med, Temuco, Chile
[2] Univ La Frontera, Ctr Res Epidemiol Econ & Oral Publ Hlth CIEESPO, Fac Dent, Temuco, Chile
[3] Univ La Frontera, Ctr Res & Innovat Clin Dent CIDIC, Fac Dent, Temuco, Chile
[4] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England
[5] Univ Melbourne, Melbourne Dent Sch, Parkville, Vic, Australia
[6] Univ La Frontera, Dept Pediat Dent & Orthodont, Fac Dent, Manuel Montt 112, Temuco, Chile
关键词
Pit and fissure sealants; Dental caries; Prevention; Cost-effectiveness analysis; AMERICAN-DENTAL-ASSOCIATION; FISSURE SEALANTS; ECONOMIC-EVALUATION; CARIES; PIT; RECOMMENDATIONS; ADOLESCENTS;
D O I
10.1186/s12903-019-0990-3
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Evidence of the cost-effectiveness of school-based first permanent molar sealants programs is not yet fully conclusive. The aim of this study was to determine the incremental cost-utility ratio (ICUR) of school-based prevention programs for the application of sealants in molars of schoolchildren compared with non-intervention. Methods: A cost-utility analysis based on a Markov model was carried out using probability distribution. The utility was measured in quality-adjusted tooth years (QATY). The assessment was carried out from the public payer's perspective with a six-year time horizon. Costs and benefits were discounted at 3% per year. Only direct costs were evaluated, expressed in Chilean pesos (CLP) at 7th May at 2019 values (exchange rate USD = CLP 681.09). Univariate deterministic sensitivity analysis and probabilistic analysis were carried out. Results: After a six-year follow up, the cost of sealing all first permanent molars was found to be higher than nonintervention, with a mean cost difference of USD 1.28 (CLP 875) per molar treated. The "seal all" strategy was more effective than non-intervention, generating 0.2 quality-adjusted tooth years more than non-intervention. The ICUR of the "seal all" strategy compared to non-intervention was USD 6.48 (CLP 4,412) per quality-adjusted tooth years. The sensitivity analysis showed that the increase in caries was the variable which most influenced the ICUR. Conclusions: A school-based sealant program is a cost-effective measure in populations with a high prevalence of caries.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Cost-Utility of Treatments for Pulmonary Arterial HypertensionA Markov State-Transition Decision Analysis Model
    Margaret C. Garin
    Leslie Clark
    Elinor C. G. Chumney
    Kit N. Simpson
    Kristin B. Highland
    Clinical Drug Investigation, 2009, 29 : 635 - 646
  • [32] Cost-Utility of Treatments for Pulmonary Arterial Hypertension A Markov State-Transition Decision Analysis Model
    Garin, Margaret C.
    Clark, Leslie
    Chumney, Elinor C. G.
    Simpson, Kit N.
    Highland, Kristin B.
    CLINICAL DRUG INVESTIGATION, 2009, 29 (10) : 635 - 646
  • [33] Tibial nerve decompression for the prevention of the diabetic foot: a cost-utility analysis using Markov model simulations
    Sarmiento, Samuel
    Pierre, James A., Jr.
    Dellon, A. Lee
    Frick, Kevin D.
    BMJ OPEN, 2019, 9 (03):
  • [34] Cost-Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model
    Lai, Chun-Huang
    Shi, Hon-Yi
    Tsai, Cheng-En
    Yang, Yuan-Chieh
    Chiu, Si-Un Frank
    CANCERS, 2024, 16 (04)
  • [35] Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis -: Cost-utility analysis using a Markov model
    Kreck, Simon
    Klaus, Jochen
    Leidl, Reiner
    von Tirpitz, Christian
    Konnopka, Alexander
    Matschinger, Herbert
    Koenig, Hans-Helmut
    PHARMACOECONOMICS, 2008, 26 (04) : 311 - 328
  • [36] Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial
    Lanzeta, Itziar
    Mar, Javier
    Arrospide, Arantzazu
    GACETA SANITARIA, 2016, 30 (05) : 352 - 358
  • [37] Cost-utility of a biofilm-disrupting gel versus standard of care in chronic wounds: a Markov microsimulation model based on a randomised controlled trial
    Carter, Marissa J.
    Myntti, Matthew F.
    JOURNAL OF WOUND CARE, 2019, 28 (07) : S24 - S38
  • [38] COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL
    Nguyen, C. M.
    Mendes, M.
    Bounthavong, M.
    Christopher, M.
    Morreale, A. P.
    VALUE IN HEALTH, 2010, 13 (03) : A127 - A128
  • [39] Cost-utility analysis using a Markov model to compare prescription statins versus potential over the counter statins in USA
    Gandhi, P. K.
    McGhan, W. F.
    Peterson, A. M.
    VALUE IN HEALTH, 2006, 9 (06) : A352 - A352
  • [40] Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model
    Patel, Jignesh J.
    Mendes, Margaret A. S.
    Bounthavong, Mark
    Christopher, Melissa L. D.
    Boggie, Daniel
    Morreale, Anthony P.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2012, 18 (02) : 247 - 255